What is the recommended treatment for stage III invasive micropapillary breast cancer in an adult patient?

Treatment for Stage III Invasive Micropapillary Breast Cancer

Stage III invasive micropapillary breast cancer should be treated with neoadjuvant systemic therapy first (not surgery), followed by surgery and radiation therapy in a combined multimodal approach. 1

Initial Workup and Staging

Before initiating any treatment, obtain:

• Core biopsy with biomarker analysis (ER, PR, HER2, proliferation/grade) - this is indispensable for treatment decisions 1
• Complete staging workup including history, physical exam, lab tests, and imaging of chest and abdomen (preferably CT) and bone imaging, as stage III patients have significant metastatic disease risk 1

Primary Treatment Approach: Neoadjuvant Systemic Therapy

Systemic therapy must be the initial treatment - not surgery or radiation. 1 The specific regimen depends on tumor biomarkers:

For Triple-Negative IMPC (ER-/PR-/HER2-)

• Stage II-III: Pembrolizumab + carboplatin + paclitaxel, followed by pembrolizumab + cyclophosphamide + doxorubicin or epirubicin, then adjuvant pembrolizumab (Category 1) 2
• Alternative: Anthracycline-and-taxane-based chemotherapy 1

For HER2-Positive IMPC

• Concurrent taxane and anti-HER2 therapy (increases pathologic complete response rates) 1
• Anthracycline-based chemotherapy should be incorporated but administered sequentially with anti-HER2 therapy (not concurrently) 1
• Pertuzumab-based regimens are acceptable for early-stage disease 3

For Hormone Receptor-Positive IMPC (ER+ and/or PR+)

• Options include anthracycline-and-taxane-based chemotherapy OR endocrine therapy 1
• Choice depends on:
  • Tumor characteristics: grade, biomarker expression levels
  • Patient factors: menopausal status, performance status, comorbidities, preferences 1
• If endocrine therapy chosen: aromatase inhibitor preferred for postmenopausal women 4, 5

Important caveat: While IMPC is aggressive with high lymphovascular invasion rates 6, 7, recent evidence suggests it responds well to neoadjuvant chemotherapy with similar partial response rates to invasive breast cancer of no special type 8. This supports the use of NAC in IMPC patients.

Surgical Management After Neoadjuvant Therapy

Following effective neoadjuvant systemic therapy:

• Mastectomy with axillary dissection is recommended in the vast majority of stage III cases 1
• Breast-conserving surgery may be possible in selected patients with good response 1
• For patients achieving good response, breast-conserving therapy (BCT) is at least equivalent to mastectomy in survival outcomes for IMPC 9

If disease remains inoperable after systemic therapy and radiation: "palliative" mastectomy should NOT be performed unless surgery will result in overall improvement in quality of life 1

Radiation Therapy

• Required based on pre-chemotherapy characteristics to chest wall and supraclavicular lymph nodes 3
• Strongly consider including internal mammary lymph nodes in the radiation field (Category 2B) 3
• Loco-regional radiotherapy is required even when pathologic complete response is achieved 1

Adjuvant Systemic Therapy Post-Surgery

Complete the treatment plan with:

1. Finish planned chemotherapy if not completed preoperatively
2. Endocrine therapy (Category 1) for ER+ and/or PR+ tumors - given sequentially after chemotherapy 3, 10, 3
3. Complete up to 1 year of trastuzumab if HER2+ (Category 1) - can be given concurrently with radiation and endocrine therapy 3, 10, 3
4. For triple-negative with residual disease after preoperative therapy: Consider capecitabine 2
5. For germline BRCA1/2 mutations: Consider olaparib 2

Critical Pitfalls to Avoid

• Do not start with surgery - systemic therapy must come first in stage III disease 1
• Do not give anthracyclines concurrently with trastuzumab - administer sequentially 1
• Do not omit radiation even with excellent response to chemotherapy 1
• Monitor for typhlitis in patients receiving taxane-based chemotherapy, particularly with HER2-targeted therapy - this is a rare but potentially life-threatening complication requiring early recognition and possible surgical intervention 6

A combined treatment modality based on multidisciplinary approach (systemic therapy, surgery, and radiotherapy) is strongly indicated in the vast majority of stage III cases. 1